Why do some men with elevated prostate specific antigen (PSA) levels who are carefully monitored and undergo repeated negative biopsies still develop aggressive prostate cancer? Clinical researchers at Princess Margaret Hospital (PMH) in Toronto, Canada believe they can now answer that baffling question.
In patients with prostate cancer undergoing prostatectomy, Magnetic Resonance Imaging (MRI) can play an important role in determining if the cancer is restricted to the prostate gland or if it has spread beyond the capsule.
This is the finding of a study performed at the University of California, Los Angeles, CA. The study included a review of 119 patients who were referred for prostate MRI prior to prostatectomy.
“Results showed that MRI correctly identified 87 out of 92 (95%) of patients with T2 and 6 out of 8 (75%) of patients with T3 disease (T2 means the disease is organ confined and T3 means the disease has locally spread beyond the prostate),” said Timothy McClure, MD, lead author of the study. Steven Raman, MD, worked with Dr. McClure on this study.
Magnetic resonance-guided focused ultrasound surgery (MRgFUS), a noninvasive thermal ablation technique that has been shown to be clinically effective in the treatment of uterine fibroids, is now being evaluated as a method for treating painful bone metastases.
Now physicians in North America are running a full scale clinical trial to see if the method really does work as well or better than traditional pain management methods.